Pyxis Oncology, Inc.
PYXS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $16,146 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $475 | $0 | $0 | $0 |
| Gross Profit | $15,671 | $0 | $0 | $0 |
| % Margin | 97.1% | – | – | – |
| R&D Expenses | $58,747 | $49,586 | $86,129 | $51,054 |
| G&A Expenses | $25,420 | $32,610 | $37,352 | $18,663 |
| SG&A Expenses | $25,420 | $32,610 | $37,352 | $18,663 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $20,964 | $0 | $0 | $0 |
| Operating Expenses | $105,131 | $82,196 | $123,481 | $69,717 |
| Operating Income | -$89,460 | -$82,196 | -$123,481 | -$69,717 |
| % Margin | -554.1% | – | – | – |
| Other Income/Exp. Net | $9,965 | $8,406 | $2,764 | -$6,258 |
| Pre-Tax Income | -$79,495 | -$73,790 | -$120,717 | -$75,975 |
| Tax Expense | -$2,164 | $0 | $0 | $0 |
| Net Income | -$77,331 | -$73,790 | -$120,717 | -$75,975 |
| % Margin | -478.9% | – | – | – |
| EPS | -1.32 | -1.85 | -3.57 | -2.53 |
| % Growth | 28.6% | 48.2% | -41.1% | – |
| EPS Diluted | -1.32 | -1.85 | -3.57 | -2.53 |
| Weighted Avg Shares Out | 58,446 | 39,905 | 33,033 | 32,223 |
| Weighted Avg Shares Out Dil | 58,446 | 39,905 | 33,033 | 32,223 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,039 | $6,630 | $2,764 | $23 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,982 | $1,927 | $709 | $647 |
| EBITDA | -$65,514 | -$80,269 | -$122,772 | -$69,070 |
| % Margin | -405.8% | – | – | – |